Bio

Bobby Bal is a managing director in the firm’s corporate advisory business, with a focus on the biopharmaceutical sector. Since joining Evercore, Mr. Bal has been involved in numerous strategic and financing transactions, including advising Jazz Pharmaceuticals on its pending acquisition of GW Pharmaceuticals, AstraZeneca on its pending acquisition of Alexion, Alnylam on its strategic financing collaboration with Blackstone, Lilly on its acquisition of Dermira, and Bristol-Myers Squibb on its acquisition of Celgene. Prior to joining Evercore, Mr. Bal was a director in the M&A group at UBS Investment Bank. Mr. Bal received a B.S. in finance from Virginia Tech.